Table 3. Changes in baseline to endpoint measures for oxidative stress and inflammatory biomarkers in 2 groups.

Characteristics		Placebo (n = 21)	Ellagic acid (n = 22)	P1
IL-6
	Baseline	9.46 ± 0.99	9.65 ± 0.64	0.440
	2 mon change	9.25 ± 1.00	6.66 ± 0.54	< 0.001
	P2	0.711	< 0.001
	Mean change	−0.21 ± 0.01	−2.99 ± 0.10	0.002
CRP (μM)
	Baseline	12.12 ± 0.72	11.77 ± 0.82	0.140
	2 mon change	12.00 ± 0.79	7.95 ± 0.33	< 0.001
	P2	0.270	< 0.001
	Mean change	−0.12 ± 0.07	−3.82 ± 0.49	0.001
TAC (μmol/L)
	Baseline	1.28 ± 0.48	1.08 ± 0.20	0.080
	2 mon change	1.25 ± 0.35	3.02 ± 0.62	< 0.001
	P2	0.555	< 0.001
	Mean change	−0.30 ± 0.13	1.94 ± 0.42	< 0.001
MDA (μmol/L)
	Baseline	2.17 ± 0.24	2.55 ± 0.59	0.008
	2 mon change	2.06 ± 0.18	0.89 ± 0.17	< 0.001
	P2	0.509	< 0.001
	Mean change	−0.11 ± 0.06	−1.66 ± 0.42	< 0.001

P1: comparison of the mean of oxidative stress biomarkers and inflammatory factors between 2 groups (independent samples t-test). P2: comparison of the mean of oxidative stress biomarkers and inflammatory factors in each group at the baseline and end of the study (paired samples t-test).

CRP, C-reactive protein; IL-6, interleukin-6; MDA, malondialdehyde; TAC, total antioxidant capacity.